Home › Funds › BAKER BROS. ADVISORS LP › EWTX

BAKER BROS. ADVISORS LP position in EWTX

EDGEWISE THERAPEUTICS INC · Health Care

BAKER BROS. ADVISORS LP reported holding 3,701,719 shares of EWTX (EDGEWISE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$150.4M, representing 0.79% of its reported portfolio and ranking #21 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed EWTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)3.70M sh
Reported value held$150.40M
Portfolio Weight0.79%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BAKER BROS. ADVISORS LP's EWTX position evolved

BAKER BROS. ADVISORS LP first disclosed a stake in EWTX in Q3 2023 at 1,049,699 shares (US$6.0M). The position peaked in Q1 2026 at 6,575,940 shares, worth US$207.1M. Across 12 filings, BAKER BROS. ADVISORS LP increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 3,701,719 shares valued at US$150.4M — a reduction of -2,874,221 shares quarter over quarter.. Notable position changes include a 197% increase in Q4 2023 (shares rose 67% over the following quarter), a 88% increase in Q1 2024 (shares fell 1% over the following quarter), a 44% trim in Q2 2026 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.05M $6.01M New
Q4 2023 3.11M $34.05M Add
Q1 2024 5.84M $106.52M Add
Q2 2024 5.84M $105.18M Hold
Q3 2024 5.84M $155.87M Hold
Q4 2024 6.16M $164.36M Add
Q1 2025 6.16M $135.43M Hold
Q2 2025 7.31M $95.78M Add
Q3 2025 7.31M $118.50M Hold
Q4 2025 6.58M $163.18M Reduce
Q1 2026 6.58M $207.14M Hold
Q2 2026 3.70M $150.40M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About EWTX and 13F data

EWTX (EDGEWISE THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in EWTX — the largest reported positions include ORBIMED ADVISORS LLC (US$630.5M), Paradigm Biocapital Advisors LP (US$415.1M), RA CAPITAL MANAGEMENT, L.P. (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding EWTX

All EWTX fund holders →

FAQ

How long has BAKER BROS. ADVISORS LP held EWTX?

BAKER BROS. ADVISORS LP has disclosed EWTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is BAKER BROS. ADVISORS LP's current position in EWTX?

As of Q2 2026, BAKER BROS. ADVISORS LP holds 3.70M shares of EWTX (EDGEWISE THERAPEUTICS INC), valued at $150.40M, representing 0.79% of its reported portfolio and ranking #21.

Has BAKER BROS. ADVISORS LP been buying or selling EWTX?

In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP reduced its position in EWTX. The position peaked in Q1 2026 at 6.58M shares.

Which other funds hold EWTX?

Other major institutional holders of EWTX include ORBIMED ADVISORS LLC, Paradigm Biocapital Advisors LP, RA CAPITAL MANAGEMENT, L.P., among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.